WIXOM, Mich., Nov. 17 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. , a leading, innovative dialysis products manufacturer serving the healthcare industry, reported today that it has formed a Scientific Advisory Board (SAB) to advise the Company on its clinical development and market preparation for its proprietary iron-delivery product, Soluble Ferric Pyrophosphate. The SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval. The SAB's role is to provide direction and guidance as the product moves through the FDA approval process.
The SAB is comprised of:
* Anatole Besarab, MD, Director of Clinical Research, Division of Nephrology and Senior Staff Physician, Henry Ford Hospital, Detroit
* Rajiv Agarwal, MD, Associate Professor of Medicine, Indiana University School of Medicine, Indianapolis
* Ajay Gupta, MD, Associate Professor of Medicine, Division of Nephrology, UCLA and Drew University Schools of Medicine, Los Angeles
* Bert Spilker, PhD, MD, President Bert Spilker & Associates, LLC
* Nancy Chew, M.S., RAC President, Regulatory Affairs, North America LLC
Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We have assembled an extraordinary group of world-class nephrologists and clinicians who are leaders in the area of renal anemia and iron therapy to advise us as we advance through our Phase III development program for our proprietary iron-delivery product. The SAB will play an important role in the achievement of both short- and long-term objectives for our Soluble Ferric Pyrophosphate development. We are extremely pleased that such brilliant individuals have joined us in our efforts to develop and commercialize this revolutionary iron-delivery product."
Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased approximately 6%-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate(R) Dry Acid Concentrate Mixing System, RenalPure(R) Liquid Acid Concentrate, SteriLyte(R) Liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Visit Rockwell's website at http://www.rockwellmed.com for more information.
Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.
Rockwell Medical Technologies, Inc.CONTACT: Thomas Klema of Rockwell Medical Technologies, Inc.,+1-248-960-9009
Web site: http://rockwellmed.com/
